The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended grant of ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
RANCHO CUCAMONGA - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced Monday it has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a ...
As of Tuesday, January 13, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 7.83%, which has investors ...
Most women are unaware that their bones reach their maximum strength by about thirty years of age.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, ...
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 202 ...
Dec. 30, 2025 – updated Jan. 5, 2026 – Injectable GLP-1 drugs have transformed obesity treatment – and now they're going oral. "It's good to have more options for patients with obesity," said Melanie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results